NCT01986348View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

PHASE2TerminatedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 3, 2014

Primary Completion Date

January 23, 2020

Study Completion Date

January 23, 2020

Conditions
GlioblastomaGlioma
Interventions
DRUG

Selinexor

One cycle is 28 days (4 weeks).

Trial Locations (6)

10032

Columbia University, Herbert Irving Comprehensive Cancer Center, New York

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Center for Neuro-Oncology, Boston

DK-2100

The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen

9713 GZ

University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen

3008AE

Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit, Rotterdam

Sponsors
All Listed Sponsors
lead

Karyopharm Therapeutics Inc

INDUSTRY

NCT01986348 - Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | Biotech Hunter | Biotech Hunter